Black Diamond Therapeutics, Inc. BDTX
Set alert
At close · Oct 30
After hours · Oct 30, 7:28 PM ET
- YTD
- -26.75%
- 1 year
- -53.40%
- Open
- 1.86
- Prev close
- 1.86
- Mkt cap
- 102.27M
- Vol
- 520.16K
- Avg vol
- 685.61K
- EPS
- -0.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.76
- High
- 1.90
- Forward P/E
- -1.80
- Beta
- 2.52
- Short ratio
- 11.67
- Inst. own
- 98.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 2.79
- 200-d avg
- 4.63
- 1y target
- 14.50
1m chart
Built from the cached one-day intraday bars.
Signals (26)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 29, 3:57 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:49 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:46 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:33 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:11 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:28 PM | 2 days ago |
| RSI: Overbought | Oct 29, 2:08 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:53 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:53 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:53 PM | 2 days ago |
| RSI: Oversold | Oct 29, 1:47 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:34 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:33 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:14 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:08 PM | 2 days ago |
| RSI: Oversold | Oct 29, 12:51 PM | 2 days ago |
| RSI: Oversold | Oct 29, 12:34 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:32 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:21 AM | 2 days ago |
| RSI: Oversold | Oct 29, 10:53 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:42 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:34 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 2 days ago |
Key statistics
- Market cap
- 123.92M
- Enterprise value
- 35.94M
- Trailing P/E
- 0.00
- Forward P/E
- -1.80
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.27
- EPS (TTM)
- -1.33
- Beta
- 2.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -34.59M
- Total cash
- 112.68M
- Total debt
- 23.00M
- Return on equity
- -63.09%
- Shares outstanding
- 56.59M
- Short % of float
- 18.22%
- 50-day average
- 2.79
- 200-day average
- 4.63
Analyst view
Consensus: none
- Target (low)
- 9.00
- Target (mean)
- 14.50
- Target (high)
- 20.00
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.31167.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.37 | -0.28 | +0.09 | +24.32% |
| Aug 6, 2024 | Jun 1, 2024 | -0.39 | -0.36 | +0.03 | +7.69% |
| Aug 6, 2024 | Jun 1, 2024 | -0.39 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.44 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.44 | -0.35 | +0.09 | +20.45% |
| Mar 12, 2024 | Dec 1, 2023 | -0.47 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 8, 2024 | Wedbush | reit | Outperform | Outperform |
| Sep 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2024 | Piper Sandler | main | Overweight | Overweight |
| Sep 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- blackdiamondtherapeutics.com
News
- HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- US Stocks Mixed; Dollar Tree Posts Upbeat Earnings
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
- Nanobiotix, NanoString Technologies And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Your note
Sign in to keep a note on BDTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEHBAHANI ALI | Director | Stock Award(Grant) | Dec 12, 2024 | 4,512,090 |
| BIOTECH GROWTH N.V. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 16, 2023 | 0 |
| CAMPBELL SHANNON | Director | Stock Award(Grant) | Dec 12, 2024 | 8,865 |
| DIXON WENDY L | Director | Stock Award(Grant) | Mar 14, 2024 | 38,054 |
| EPSTEIN DAVID M | Chief Executive Officer | Sale | Jun 26, 2023 | 936,569 |
| JONES ERIKA | Officer | Stock Award(Grant) | Feb 12, 2023 | 10,150 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.97% | 10,734,389 | 23.51M | Sep 29, 2024 |
| Bellevue Group AG | 15.05% | 8,517,839 | 18.65M | Sep 29, 2024 |
| Vestal Point Capital, LP | 8.89% | 5,028,500 | 11.01M | Sep 29, 2024 |
| NEA Management Company, LLC | 7.86% | 4,448,757 | 9.74M | Sep 29, 2024 |
| Blackrock Inc. | 6.18% | 3,497,766 | 7.66M | Sep 29, 2024 |
| Vanguard Group Inc | 4.10% | 2,318,011 | 5.08M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Small-Cap Value Fund | 4.53% | 2,560,552 | 5.61M | Sep 29, 2024 |
| Price (T.Rowe) Small Cap Stock Fund | 4.43% | 2,508,412 | 5.49M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.35% | 1,329,831 | 2.91M | Sep 29, 2024 |
| Price (T.Rowe) Institutional Small-Cap Stock Fund | 2.18% | 1,236,268 | 2.71M | Sep 29, 2024 |
| Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 2.18% | 1,234,985 | 2.70M | Sep 29, 2024 |
| Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.13% | 1,208,091 | 2.65M | Sep 29, 2024 |